Beta radiation has a long history as a treatment modality in ophthalmology. It is a convenient and practical method of applying radiation and has the advantage of minimal tissue penetration. There has been a recent resurgence in the use of beta radiation in other areas in medicine, such as the prevention of restenosis after coronary artery stenting. Beta radiation has been shown in vitro and in vivo to inhibit proliferation of human Tenon's fibroblasts, which enter a period of growth arrest but do not die. Effects on the cell cycle controller p53 have been shown to be important in this process.
Introduction
Beta radiation is a convenient and practical method of applying ionising radiation focally and may be precisely applied to ocular structures. Scarring in ocular structures is a major pathogenic factor in many eye diseases: both in the context of a neovascular scarring process such as in exudative age-related maculopathy and in dysfunctional, inappropriate, or excessive wound healing. There is a resurgence of interest in the role of beta radiation in other medical disciplines. In vascular medicine and cardiology, the use of beta radiation in the prevention of restenosis following coronary balloon angioplasty or stenting is highly topical. Placement of 32 P wires markedly reduced subsequent restenosis rates in a recently reported randomised controlled trial, and extensive investigation continues in this field. 1, 2 In ophthalmology, the role of both external beam radiation and brachytherapy in the management of age-related macular degeneration (ARMD) and the role of beta radiation in trabeculectomy are currently under evaluation. It is therefore appropriate to revisit the role of beta radiation in ophthalmology.
Beta radiation
Beta radiation is a particulate radiation consisting of high-speed electrons, which are rapidly attenuated by biological tissues (2 MeV beta particles have a range of only 1 cm in water). This makes it very useful for superficial radiation treatments where deep tissue penetration is undesirable. Strontium-90 ( 90 Sr), an unstable fission product of uranium-235 ( 235 U), has been found to be a clinically useful source of beta radiation as it has a long half-life (28.7 years) and emits only high-energy beta particles as it decays. Ruthenium-106 ( 106 Ru) primarily emits beta radiation but also emits a small but significant gamma component. 3 106 Ru has been primarily used in the treatment of choroidal melanoma. 4, 5 Penetration depends on the energy of particles released in the decay process of a particular source. Of emitters used in ophthalmology, the 90 Sr source has the most marked attenuation in biological tissues, making it particularly suitable for use in ocular surface treatment. The half thickness of 90 Sr is 1.5 mm, that is, the radiation dose rate is attenuated by 50% after 1.5 mm penetration through waterFthe corresponding distance for 106 Ru is 2.4 mm. One potential problem with beta radiation is in the generation of secondary X-rays, termed Bremsstrahlung, caused by braking of the highenergy electrons by the material the source is embedded in. This may also be relevant if the material is shielded by very proximally placed material with a high atomic number (eg lead). The production of Bremsstrahlung is usually minimal with the low atomic number atoms found in biological soft tissues.
Method of delivery
The 90 Sr source is commercially available for use in pterygium surgery (Nycomed Amersham, UK) ( Figure 1 ). The sources remain clinically useful for at least 10 years. Recalculation of the dose rate is required periodically as the activity of the emitter slowly decays.
Typically, this is done every 6 or 12 months. These sources have also been used with trabeculectomy. The dimensions of this source, 11 mm diameter (round) and 3 mm thickness, are not ideal for trabeculectomy, as excellent exposure is required for application. However, smaller sources are also available (BEBIG, Berlin). In future, a custom-shaped device may be available. The source we are using is available with a mask to allow delivery to particular areas; however, to ensure reliable dosimetry, we use these without masking. The dose rate depends on the individual characteristics of a particular source and how much 90 Sr is in a particular emitter. With a new source, a dose of 1000 cGy (rad) may be administered over approximately 20 s. After some years, the exposure time may be in the order of several minutes.
Cellular effects of beta radiation
The fundamental biological effect of ionising radiation is the process of ionisation, where the absorption of energy by an atom or molecule results in the ejection of one or more of its orbiting electrons, resulting in unstable and highly reactive compounds. From its earliest clinical use, it has been clear that radiation influences tissue healing. 6 In 1932, Desjardins noted that a proportion of irradiated cells exhibited either a temporary inhibition of metabolic activity, or a complete and permanent disintegration, and in 1957, Puck et al demonstrated that the growth of normal fibroblasts in vitro could be inhibited by radiation. 7, 8 In the eye, radiation has been shown to inhibit corneal wound healing, with prominent effects on fibroblast proliferation. 9 Radiation therapy has also been utilised as a means of preventing proliferative vitreoretinopathy (PVR).
10,11
The conjunctival fibroblast is at the core of the healing response following trauma to the conjunctiva; their proliferation, contraction, collagen production, and eventual quiescence determine the extent of the overall wound healing response. In rabbit models, which show a considerably more aggressive healing response than man, focal beta radiation attenuates wound healing and prolongs bleb survival. 12, 13 These studies demonstrated reduced fibroblast numbers, without excessive inflammation. Additionally, collagen deposition and bleb thickness tended to be reduced. Concerns that focal beta radiation treatment may actually induce rather than inhibit postoperative inflammation have not been borne out, however, either in animal models or in clinical practice. 12, 14 The first in vitro experimental data on beta radiation on ocular cells were published by Nevarez et al 15 in 1987, who studied proliferation of cultured monkey fibroblasts following single doses of irradiation. Proliferation was reduced to 14% with doses of 1000 cGy or more in this examined the effect of beta radiation on human Tenons fibroblasts over a longer time period and examined the effect on cell cycling. They showed that dose-dependent inhibition of human Tenon's fibroblast proliferation up to a plateau at exposures of 1000 cGy is due to cellular growth arrest rather than to cell killing. Cellular p53 levels were also measured. p53 is a neuropeptide that prevents cell replication in the presence of DNA damage, that is, it acts as a 'guardian of the genome'. Levels of p53 were found to be significantly increased over the 30-day study period, presumably in response to DNA damage caused by the radiation.
One important issue is how these cellular effects compare to those of 5-fluorouracil (5FU) and mitomycin C (MMC). Khaw et al showed that 5FU (25 mg/ml) and MMC (0.1 mg/ml) both reduce fibroblast proliferation by at least 50% by inducing growth arrest in a manner similar to that following radiation. However, the effects of MMC do differ in an important way. Single applications of 0.4 mg/ml MMC rapidly lead to high levels of cell death by apoptosis, an effect not seen after clinically relevant doses of radiation. 18 
Suseptibility of ocular structures to radiation damage
The safety of any therapeutic approach is of paramount importance and there are considerable data on the radiosensitivity of the ocular structures to ionising radiation. Chalupecky 19 first studied the effects of radiation on the eye over 100 years ago. Current data on the susceptibility of ocular structures to radiation are summarised in Table 1 .
Radiation and the lens
The lens has been recognised for many years to be the most radiosensitive structure in the eye. Many clinical and experimental studies have been published investigating the tolerance of the lens to radiation.
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Cataracts have not been reported with lens doses of radiation below 200 cGy, but nonprogressive lens changes have been sporadically recorded with doses just above this level. Merriam et al 23 concluded that the minimum cataractogenic dose for a single treatment was 200 cGy to the lens epithelium, with the probability of cataract approaching unity for a dose of 750 cGy, although only 50% of these cases showed progressive change. The latent period for the onset of these lens opacities has been reported as varying between 6 months and 35 years, and appears to be inversely related to the total dose administered. Hilgers 20 concluded that a surface dose (ie to the bare sclera) of 3000 cGy could be considered a safe noncataractogenic dose of 90 Sr beta radiation. Given the dose considerations above, the degree of penetration of beta radiation is crucial. Although the events leading to lens opacity are not fully understood, the germinative zone in the lens epithelium is considered to be the most important area. This part of the lens is relatively close to the limbus and may receive a particularly high proportion of radiation compared to the whole lens when beta radiation as applied to the anterior segment. Dose to the lens has been calculated assuming exponential decay of the surface dose. Using that the dose to the germinative epithelium is approximately 14% of the surface dose applied after pterygium surgery onto the bare sclera. The additional attenuation by the conjunctiva with a thickness of approximately 1 mm means that the lens dose following application after trabeculectomy is likely to be less than 10%. 24 Attenuation is difficult to model through a structure such as conjunctiva (particularly, immediately after conjunctival surgery) because the presence of tissue, fluid, and air space causes interfaces which may have significant effects on transmission of beta radiation, that is, attenuating it further than through a homogenous medium. Individual variations in ocular anatomy, including anterior chamber depth, may also have an effect on the lens dose for a given surface dose.
In the use of trabeculectomy as a primary treatment for glaucoma in the developing world, the problem of subsequent development of lens opacity is particularly important. In a recent study from Tanzania, where trabeculectomy with mitomycin C was evaluated, 33% of patients developed significant cataract. This is clearly a major problem in such a setting where re-presentation for cataract extraction may not be feasible. There is some suggestion that trabeculectomy with mitomycin C and 5-fluorouracil may accentuate development of lens opacity more than trabeculectomy alone. The role of beta radiation in cataract progression after trabeculectomy is of great clinical importance. It is reassuring that beta radiation (750 cGy) has been used at Moorfields Eye Hospital on children and young adults for nearly 20 years and no patients have required cataract surgery. There is evidence that mitomycin C does penetrate the sclera and has intraocular effects in man, but to what degree and how often this occurs is, in clinical practice, as yet unclear.
Beta radiation in ophthalmology

Pterygium
The most common use of beta radiation has been in the management of pterygium, with local application of a 90 Sr source to prevent recurrence. Iliff suggested that beta radiation may be particularly useful in ophthalmology in 1947, following from an earlier report by Burnam; however, its usefulness was limited by the need to use naturally occurring radon seeds. [25] [26] [27] Friedell was the first to describe the clinical use of a
90
Sr source in 1950. It was suggested for a variety of uses including treatment of superficial tumours, vernal conjunctivitis, tuberculosis, and corneal vascularisation. 28 In the treatment of pterygium, initially a high dose of beta radiation was applied without surgical excision, the aim being to induce regression of the lesion. Administration after surgery, particularly for recurrent pterygia, was widely adopted, with subsequent reports indicating a low recurrence rate. Many reports were from Australia with a high prevalence and recurrence rate, presumably due to high levels of ultraviolet radiation. Adverse effects with beta radiation for pterygium have been widely reported. Earlier reports concentrated on lens opacity, conjunctival telangectasia, and other side effects of doses much higher than those used clinically after pterygium surgery. Cameron reported five subjects with varying degrees of scleral necrosis: he attributed these to poor surgical technique in four cases (excessive cautery) and overdosage (7200 cGy) in another. Subsequently, Tarr and Constable reported a large series of eyes from western Australia. They reported 51 cases of scleral ulceration. The time lag between therapy and presentation was between 3 and 20 years, mean 12 years. They estimated a 2.6% rate of significant scleral necrosis in the long term after treatment. In all but one of the cases the patients had received at least 2400 cGy. 35 One patient received 750 cGy and developed a small (1.5 mm diameter), punched-out ulcer covered with 'slightly' abnormal conjunctiva 10 years later. The other ulcers were larger, frequently very deep, with avascular conjunctival covering. Subsequent reports from the same centre reported on infective scleritis, with devastating ocular consequences, all patients having received over 2000 cGy. 36 A subsequent report suggested that using lower doses was also associated with scleral infection. Mackenzie reported long-term follow-up (10 years) on 585 of an original 1102 patients in Queensland, Australia. Overall recurrence rate was 12%. It was reported that 13% of eyes had some degree of scleral thinning and 4.5% had a significant degree of scleral thinningFdefined as at least 50% reduction in scleral thickness over an area at least 2 mm in diameter. The surgery was performed using a bare sclera technique and it is possible that this exacerbated the risk of late melting. Use of beta radiation for pterygium has diminished, with conjunctival autografting and topical mitomycin C now being widely used. Currently, there is no conclusive Eye b-irradiation: a review JF Kirwan et alevidence as to the optimum therapy conjunctival autografting is reasonably effective and appears to be safe; however, it is considerably more time consuming than other methods. 37 Comparative data for beta radiation and mitomycin C are conflicting: a retrospective comparison from Japan suggested that mitomycin C was more effective; a study from Turkey suggested the converse, a Dutch study suggested equivalence; and a randomised controlled study from Australia suggested that beta radiation was more effective than either conjunctival autografting or mitomycin C. [38] [39] [40] [41] While initial reports indicated good safety with mitomycin C, late complications of mitomycin C use, including scleral necrosis and corneal perforation, have been reported that are remarkably similar to those of beta radiation.
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Age-related macular degeneration
In recent years, there has been persisting interest in the role of ionising radiation in the management of exudative ARMD following the first report by Chakravarthy et al 45 using external beam therapy. Radiation has been shown to inhibit vascular endothelial cell proliferation and angiogenesisFboth of which are key elements in the development of choroidal neovascularisation. [46] [47] [48] The use of external beam treatment necessitates fractionation as individual doses of more than 500 cGy or regimes with a total dose of more than 5000 cGy result in unwanted side effects. 23, 49 However, the dose required to induce regression of vascular tissues in clinical practice is close to this level. 50, 51 Given these considerations, an alternative approach has been the use of an episcleral plaque placed close to the area of treatment. Brachytherapy has utilised either palladium-103 ( 103 P), a low-energy gamma emitter, or 90 Sr. Studies have reported doses of between 500 and 2400 cGy to the target tissue. 52, 53 Dosimetric studies have demonstrated that a local approach leads to a considerably smaller radiation dose to the lens and optic nerve than for external beam therapy. When these doses are administered by an external beam, the dose given to the lens may be sufficient to induce cataract, as up to 50% of the maximum dose may fall on the posterior lens. The disadvantages include the need for incisional surgery. Whether these theoretical differences provide any practical advantage remains to be seen, however, external beam radiation has not been shown to be effective in trials reported so far.
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Glaucoma drainage surgery
The earliest publication specifically addressing the use of beta radiation with drainage surgery was by Iliff in 1944.
In a review of surgical management of glaucoma in African-Americans, he reported an overall success rate of 40% in a historical control group, with eight of 11 cases receiving beta radiation having a successful outcome with at least 1-year follow-up. He reported that 'post operative beta radiation gave encouraging results, and was worthy of further trial'. 25 A further report by Cohen et al 57 using a
90
Sr emitter showed success in eight of 10 patients. Cameron 58 reported success in a small series from Australia on patients that had previously failed surgery. 58 In 1991, Miller and Rice 14 published the follow-up data in a series of 66 eyes with congenital glaucoma, 31 of which had been treated with 750 cGy beta radiation at the end of surgery. Analysis at 3 years showed that beta radiation was significantly protective against failure as compared to controls. O'Donoghue et al 59 presented 1-year follow-up of a randomised controlled trial of beta radiation compared with postoperative 5-fluorouracil. They concluded that the antiscarring effect of these two treatments was similar, but importantly that fewer of the irradiated eyes developed cystic blebs or corneal toxicity. 59 In the same year, Lai and Ho presented their 1-year results in a prospective trial of the use of beta radiation combined with trabeculectomy compared to trabeculectomy alone in a cohort of uncomplicated cases of primary open-angle glaucoma in Hong Kong. Surgical failure was significantly reduced in the irradiated eyes (9.52%) compared to the control eyes (26.09%). 60 Barnes et al 61 recently reported on the use of beta radiation in white subjects with a low risk of failure. They did not see a significant difference in intraocular pressure or failure rate as there was a high success rate in both arms of the study and the study power was very limited. 61 
Why beta radiation in glaucoma surgery
The use of antiproliferatives has revolutionised glaucoma drainage surgery. 62 However, the use of liquid antimetabolites may be associated with problems. The variability of the delivery of the drug between the impregnated sponge and the subconjunctival tissues means that accurate dosimetry has proven extremely difficult. 63 They are used in liquid form, delivered by placing microsurgical sponges soaked in the drug directly onto the operative site. Furthermore, because they are liquids, they carry the risk of leakage away from the treatment site, leading to extraocular or, more seriously, intraocular toxicity. 64, 65 Both treatments have been associated with the development of extremely thin, avascular filtration blebs, and these are associated with an increased risk of sight-threatening complications including profound hypotony and endophthalmitis. [66] [67] [68] As previously illustrated, beta radiation has certain features that may make it suitable for use in glaucoma Eye b-irradiation: a review JF Kirwan et alsurgery. Application of beta radiation is rapid and convenient, and the focal nature of application reduces the risk of accidental overdosage. Both dosimetry and the area treated can be controlled with accuracy. The size of the application area of antimetabolites has been shown to be important in the way that blebs develop, and large treatment areas seem to be more favourable. 69 This is easy to control without extensive dissection if a customsized applicator is applied to the desired area, whereas more extensive dissection is required if a large treatment area is required with a liquid antimetabolite. Additionally, there is no risk of leakage outside the treatment area, with which a liquid antimetabolite may lead to nonhealing of the wound edge. The actual nature of the bleb formed is different from that produced with MMC or 5FU, tending to be thicker and less avascular. This has been noted in clinical studies and also in animal models. 59, 70 Whether this is a result of treatment size effects or intrinsic differences between these modalities is unknown, but may be important in minimising the incidence of bleb complications including endophthalmitis (Figure 2 ).
For the developing world, there are additional practical advantages with beta radiation. The stability and long half-life of 90 Sr means that once obtained, an emitter can have a long working life (20 years plus), with only occasional recalibration. Sources are stable and easily stored, with no refrigeration required, and sustainability issues such as maintaining a good supply of drugs, and ongoing costs are not a problem. In the UK, capital outlay is currently significant (approximately UK d5000), but emitters could be made more cost-effectively. Clearly, the unit cost drops with increased turnover. Strict licensing laws may discourage use in many countries, as clinicians are required to obtain a special licence.
In comparison to its use for pterygium, beta radiation in glaucoma surgery may be safer for the following reasons. The dose of 1000 cGy used is the optimum dose as determined in in vitro and in vivo studies. 17 This is between 20 and 50% of the dose used for pterygium. Reports of scleral necrosis with this dose are extremely uncommon. The applicator is placed on the conjunctiva immediately following surgery rather than on bare sclera. This reduces the dose received by the sclera, as a significant proportion of the radiation is attenuated passing through the conjunctiva (approximately 30% assuming a thickness of 1 mm). Trabeculectomy is performed in the superior location, under the upper lid. The protection of the upper lid is important for providing protection to the bleb. It is known that interpalpebral blebs have a far greater incidence of bleb-related complications, particularly after antiscarring agents have been used. This is quite different from the situation following pterygium surgery where the bare sclera is interpalpebral and de-epithelialised. Both these factors may render the scleral tissue more susceptible to infection. Beta radiation has been used at Moorfields Eye Hospital for over 25 years in the management of paediatric glaucoma cases. During this time, the use of beta radiation has had an excellent safety profile, with no evidence of neoplastic effects or radiation-associated lens opacity.
Summary
Beta radiation is a practical method of applying radiation focally. In clinically used doses, it is effective in reducing the proliferative wound healing response, causing growth arrest without inhibiting other cellular functions. Its ocular safety profile is relatively well understood. Beta radiation has been in clinical use longer than most other methods of controlling scarring and was widely used for pterygium. Its use in that role has diminished with the uptake of other modalities, albeit without a strong supportive evidence base. Owing to its longevity, we are more aware of its long-term effects than is the case with other modalities. It may have clinical use in the management of ARMD and also for glaucoma surgery.
With the development of biotechnology-based approaches to the control of wound healing, it may be tempting to reject older and perhaps 'blunter' tools in our quest for better results. 71 However, the applicability of these approaches to the bulk of the world's glaucoma population in the near future is questionable and it is appropriate to fully exploit our current approaches to controlling ocular wound healing. As the use of beta radiation may be especially suitable for use in the developing world, particularly in Africa, we are currently performing a randomised controlled trial of beta radiation in South Africa. Patients with primary glaucoma are randomised to standard trabeculectomy or trabeculectomy augmented with 1000 cGy of beta radiation immediately after surgery. We hope that this trial will help to improve treatment options in the management of this blinding condition.
